SANUWAVE Health Inc is a medical device company providing directed energy products into the wound care space. It is focused on the commercialization of its patented regenerative medicine utilizing noninvasive ultrasound or shockwaves to produce a biological response promoting the repair and regeneration of tissue, musculoskeletal, and vascular structures. Sanuwave's patented, FDA-cleared, and commercialised product is the UltraMIST system, which is used to treat a variety of acute and chronic wounds using ultrasound technology. The company operates in one reportable segment, the design and sale of medical devices. Geographically, the company generates revenue mainly from the United States.
Last trade$1.73
Day change-$0.08 (-4.42%)
Day range$1.68 – $1.83
Volume62,450
Market cap$16M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$15.57M
Price / earnings
6.05×
Price / book
5.46×
Price / sales
0.38×
EV / sales
0.66×
EV / EBITDA
-47.41×
Profitability
Earnings per share
$0.30
Return on assets
7.91%
Return on equity
90.25%
Dividend yield
0%
Liquidity and leverage
Debt / equity
6.37×
Current ratio
1.18×
Quick ratio
0.77×
Cash ratio
0.4×
Cash flow
Price / cash flow
4.73×
Price / free cash flow
5.99×
Free cash flow
$2.6M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for SNWV, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Revenue
$8.58M
$9.74M
$9.62M
$13.09M
$11.27M
$10.05M
$9.33M
Cost of revenue
$1.95M
$2.32M
$2.19M
$3.39M
$2.53M
$2.21M
$1.96M
Gross profit
$6.63M
$7.42M
$7.43M
$9.7M
$8.74M
$7.85M
$7.38M
Selling, general and administrative
$7M
$6.83M
$7.65M
$8.19M
$7.27M
$6.04M
$6.37M
Research and development
$426K
$628K
$660K
$606K
$345K
$194K
$208K
Total operating expenses
$7.7M
$7.7M
$8.56M
$9.09M
$7.84M
$6.41M
$6.77M
Operating income
-$1.07M
-$280K
-$1.12M
$615K
$903K
$1.44M
$601K
Interest expense
-$276K
-$518K
-$546K
-$798K
-$1.8M
-$1.94M
-$1.91M
Income before taxes
-$1.35M
-$676K
-$1.44M
$6.2M
$9.69M
$551K
-$6.12M
Income taxes
$63K
$6K
$0
$86K
$0
$0
$0
Net income
-$1.42M
-$682K
-$1.44M
$6.11M
$9.69M
$551K
-$6.12M
Net income attributable to common shareholders
-$1.42M
-$682K
-$1.44M
$6.11M
$9.69M
$551K
-$6.12M
EBITDA
-$731K
$33K
-$830K
$955K
$1.15M
$1.62M
$810K
Basic earnings per share
-$0.16
-$0.08
-$0.17
$0.71
$1.13
$0.06
-$0.72
Diluted earnings per share
-$0.16
-$0.08
-$0.17
$0.64
$0.39
-$0.04
-$0.72
Recent news
Company coverage with links to the original publishers.
Sanuwave Health reported Q3 2026 revenues of $8.6 million, down 24% year-over-year, with a GAAP operating loss of $1.1 million compared to operating income of $0.9 million in Q3 2025. The decline was primarily driven by CMS proposed rule changes affecting reimbursement rates and a market 'wait and see' approach, which reduced Ultramist system sales to 40 units from 155 in the prior year. However, the company noted positive developments including a 14% increase in HOPD rates and removal of Q1 status from the 97610 code.
Sanuwave Health (NASDAQ: SNWV) reported Q2 2026 revenues of $9.7 million, down 3% year-over-year, with gross margins declining to 76.2% from 78.1%. The company posted an operating loss of $0.3 million versus operating income of $1.4 million in Q2 2025. While Ultramist applicator revenue grew 13%, system sales declined significantly due to CMS reimbursement pressures and a secondary market for used equipment. The company has withdrawn its 2026 guidance pending clarity on Medicare reimbursement developments.
Sanuwave Health (NASDAQ: SNWV) reported Q1 2026 revenues of $9.6 million, up 3.1% from $9.3 million in Q1 2025, marking the highest Q1 quarterly revenue in company history. However, gross margin declined to 77.3% from 79.0% due to wholesale pricing for resellers. The company swung to a $1.1 million operating loss from $0.6 million operating income in the prior year. Management expressed optimism about recovery beginning in February, with consumables unit volumes reaching all-time records. The company guides for Q2 2026 revenue growth of 10-15% and full-year 2026 growth of 16-25%.
Sanuwave Health, Inc. (NASDAQ: SNWV) announced it will host a conference call on May 13, 2026 at 8:30 AM ET to present Q1 2026 financial results. The company reported preliminary Q1 2026 revenue of $9.6-$9.7 million, representing a 3-4% year-over-year increase.
Sanuwave Health reported Q1 2026 preliminary revenues of $9.6-$9.7 million, representing 3-4% growth over Q1 2025 and in line with guidance. The company attributed lower-than-midpoint results to deals sliding out of the quarter due to reimbursement changes in the wound care space affecting skin substitutes and allografts. CEO Morgan Frank expressed cautious optimism about market recovery, noting strong interest in Sanuwave's Ultramist product at the SAWC conference.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.